Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

velopment for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.

NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck & Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext(TM) Paris (segment: Next Economy).

The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties document of reference. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company's documents of reference.


'/>"/>
SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...o take body temperature, for home,and clinical use...- Kidz-Med, Inc.,(subsidiary of American Scientifi... distributor of the Thermofocus(R) 5-in-1 non-cont...s of a clinical study,conducted by the Second Chil..., Italy, which proves that the Thermofocus(R) meas...
(Date:7/23/2008)... Therapy to Treat the Disease -, WAYNE, N.J. and ... --,Bayer HealthCare Pharmaceuticals and Onyx Phar...hat The New England Journal of Medicine published,...var(R) (sorafenib),tablets decreased the absolute ...ectable hepatocellular carcinoma (HCC), or liver c...
(Date:7/23/2008)...wswire/ -- The following was,released by the U.S. ... Member Smith, and Members of the Committee.,Thank... I appeared before this Committee almost six month...he talented and dedicated professionals,at the Jus...ave come to,appreciate that much more deeply their...
(Date:7/23/2008)...-- InCode BioPharmaceutics, Inc.,an emerging biop... test,results demonstrating the utility of their l...rare chronic blood disorder paroxysmal nocturnal,h...presented at the XXII,International Complement Wor... The only treatment currently available for PNH pa...
Breaking Medicine Technology:Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 1Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 2Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 3Immune Design Announces 2418 Million Series A Financing 22475 1Immune Design Announces 2418 Million Series A Financing 22475 2Immune Design Announces 2418 Million Series A Financing 22475 3John 26 Jean Piety Named SLA Engineering Librarians of the Year 22473 1John 26 Jean Piety Named SLA Engineering Librarians of the Year 22473 2Chiltern Enhances Its Portfolio of Electronic Data Capture 28EDC 29 Services With the Addition of Hosting and eCRF Design Services for DataLabs 28by 22470 1Chiltern Enhances Its Portfolio of Electronic Data Capture 28EDC 29 Services With the Addition of Hosting and eCRF Design Services for DataLabs 28by 22470 2
...tionality in Humans of CTI,s,Programmable, Pulsati...onoDose, BASEL, Switzerland and TRENTON, N.J., May... (CTI) announced today the successful,completion o...rammable, pulsatile, passive transdermal drug/devi...s to publish this,clinical data in leading scienti...
...IRE)--May 7, 2007 - NanoViricides,Inc. (Pink Shee...es,against rabies and BSL3 in vitro studies agains...rd Annual Symposium of the Pan,American Society fo...y 2. (Pan American Society for Clinical Virology (...dies against Clade 2 H5N1, a Dec. 2006 isolate in,...
Other Medicine Technology:Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3NanoViricides Drugs Found To Be Highly Effective Against Most,Recent Strain of the H5N1 Avian Flu Virus 2
(Date:7/25/2008)...er Releases Results of Fourth Annual Physician On-...DETROIT, July 25 /PRNewswire/ -- Sullivan, Cotter ...al survey of physician on-call pay rates and,pract.... The survey report,with data from 132 healthcare...all pay practices and rates paid for 33 physician ...
(Date:7/25/2008)...ionship Based on Significant Improvements in Membe...tacor, Inc., a leader in health,care quality manag...day,announced it has entered into a long-term agre...ellmark,s Collaboration on Quality(SM) Incent and,...between Wellmark and,primary care clinicians to pr...
(Date:7/25/2008)...ly 25 /PRNewswire/ -- The Elekta Family of Compani...ment solutions at the 2008,American Association of...onstrating how the joint forces of Elekta, IMPAC a...py planning and delivery solutions that,streamline...ce for,patients, as well as enhance clinician effi...
(Date:7/25/2008)...id back-up in esophagus can cause immune system ch...s) -- The first evidence linking gastroesophageal ...ed by Duke University Medical Center researchers. ... first noted in the 1970s, and since then studies ...of asthma patients also experience GERD symptoms. ...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2
...the risk of heart disease, but now researchers say...r the development of a heart attack.This is becaus... almost immediate impact on the cardiovascular sys...ents, the researchers found that those who smoked ...
...chool of Medicine have recently found that the bra...hat lets us stop smelling something, even though t... recent issue of the journal Science show that a p...‘nose’ of odour receptor cells.//The main job of t...
...inking could reduce their risk of suffering a stro.... In a new leaflet, the Stroke Association says sm...ic strokes - caused by blood clots blocking arteri...es of the brain attack.// Alcohol thins the blood...
...he South Sea Islands. It is a herb that has been i...ses. The herb is commonly used by consumers as a g...ress and muscle spasms. According to experts, the ...wn as// benzodiazepines but is not chemically rela...
Other Medicine News:
The Sphincter of Oddi Manometry Application for POLYGRAM NET™ (PNET) works with the Polygraf™ ID multiparametric recorder to record and analyze pressure signals from sphincter of Oddi man
...rise the SmartPill GI Monitoring System., ,Three ...toring System: SmartPill pH.p Capsule software, Sm...iGI software. These three components are integrate...toring System and function together with system ha...
... NET™ (PNET) works with the Polygraf™ ...pressure signals from continuous pull-through proc...cter (LES)., ,Continuous pull-through procedures ...r Puller, but they may be carried out manually wit...
... POLYGRAM NET™ works with the Polygraf&trade...e multichannel EGG signals. The EGG analysis takes...ng an automatic electrode impedance check on every...ording. If the electrode impedance is measured abo...
Medicine Products: